Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The tech is there. The company just needs to execute. I was so happy to see my current hospital look into investing in GE Carestation anesthesia machines. Much smaller footprint. Reminds me of why SPORT will be a game changer. Roll to the OR. One breaks? Get the rep to truck a temp SPORT in, roll it to the OR. Don't have to cancel cases. Can't do that with a da Vinci.
Laguvulin is amazing, about as much as SPORT.
Looks like it fell the most during the Apple event announcement of the iPhone X. Mr. Market doesn't like the device -- same ol same ol.
What a realistic demo. Anesthesia forgot to put the patient in T-berg!
Insider purchases before an offering?
There has been an awakening in the Force. Have you felt it?
This device will succeed -- it is just a matter of how much time and how much longs have to suffer. This sector of healthcare is extremely secretive because of how much money is involved. The sentiment amongst hospitals and providers is that they're tired of ISRG running the show, and that they want choice injected into the market.
Started a locums assignment at a large academic center recently, and what gives me a lot of encouragement is that the surgical residents here know about Titan. Some own shares. How they afford it I have no clue. Oh wait, because it is at 31 cents. Wah wah wah...
Titan will have its heyday. Just give it time to develop and get to more milestones.
Dr. Patel is big down here in Florida. Runs a smooth running prostate machine. He'll certainly get some da Vinci reps and other hospital crew interested in Titan. I expect guys like him want robots in a doc-owned surgical center that can't afford the price tag or size of Intuitive's line.
I'll be ready to pick up some more shares soon. Good that this is part of an index in a larger, growing market. Exploding SGN7 phones causing a little fear that will pass.
Elated? Not the right word. Relieved? Perhaps. When you're in financial stalemate to meet marks, a buyout isn't optimal but it is that ground rule double that can get your money working elsewhere. Everyone wants Titan to be a grand slam, but you have to shoot for the stars to land on the moon sometimes.
The entry floor into this market is rising every year. Titan is still leaps and bounds ahead of the competition. They haven't made many good decisions, but unlike TRXC, they haven't made any bad decisions, either. That is what makes this stock boil some blood. A nasty limbo machine. Titan has seen sub $.50 before. It will rise again. The time-cost in the technology alone is worth more.
Someone likes Titan this morning. At my new facility watching a da Vinci Si pheo. Feels like an old machine.
Thought I'd take a break from this lovely North Shore view to see what's happening on the board. Big mistake. The hindsight butthurt is still emanating. Close your ihub accts and come back next year. We'll be at $1.50 awaiting FDA after a dilution or 2. Titan isn't going to die. Too much good engineering, too far ahead of competition. Everybody will have a time to make money or sell even.
Would've should've could've gotten in at a better PPS won't change the behavior of this stock. That's 99% of what I see here. Or treating Titan's delays like they're the Honolulu rail project.
Follow the Ferrari's and McLaren's there in Banus. It will either be a potential investor...or a bumbling BBC auto show host.
Heading to the Greek Isles around the same time. Summer time blues and people wanting to get their money working in rising commodity prices makes me look at this FDA delay with less stress. I'm 30. I have the time in the world for Titan to blast off. Just keep showing the desire to do it right.
Time is money, but so is a bad product that won't sell.
Any sort of retrofitting is possible, especially pre-FDA. Ask our "Guess Who?" panel of Verb engineers donning Titan's 3D glasses.
They'll need a head start or a really ridiculously cohesive, productive team.
There are more forces now that want SPORT through on the first FDA try. Those forces are bigger. With regards to disposables, it is in their interest to have multiple robots on the market to avoid a monopsony market.
Lots of speculation on this forum, but there's also lots of premature door shutting. Longs just need to focus on the tasks at hand and what we have accomplished already. SPORT looked GREAT at Sages. Time to finish the race.
You have all freedom to spew material on here that lacks substance, and then mock longs. There's some negative nancies on here with opinions and provide substantial, respectable evidence and doubt for their case. You just come on to troll.
More indications and exercising prudence with the FDA route are superb reasons to push the timeline out. Failing something is poor, and they haven't encountered much of that, if at all. This isn't the Big Dig or some other cost overrun monstrosity.
If mgmt treats this gig like they only have one shot at it, then I won't give them much grief. Everyone should know the risks going into a business like this. You're betting on a fancy high school science project versus a game changing surgical device. The distinguishing features will appear at those binary events.
Until then, pop a benzo, drink your favorite scotch, and enjoy the summer. I'm heading to Crete.
Too much butthurt on here today from the feeling of bait-and-switch. This is an R&D stock. Have patience for the grand slam. Titan has all the tools and prudence on their side to get through FDA. There won't be any PPS increase for the sake of PPS increase. Binary events are the name of the game in this stock. That's completing milestones, studies, clearance, and the announcement (not prospect) of acquisition.
Too many people treating this stock like Ford or a commodity.
Titan has to play the high ground in the FDA matter. We saw what happened when you half-bake the job. Everyone knows the FDA is a revolving door and there are some serious strings to pull in the robotic surgery market to join the club.
I just loaded up again.
There is no non-lithium chemistry battery out there that can be as dense, stable, and affordable as the current tech. 20 years from now I don't see us off of lithium. Rather, we may be more dependent on it as our grids become more based on lithium storage. Most battery research is still using lithium in their chemistry. Li Sulfur is the next step.
Good time now to load up on shares feeding on the competition's panic a few days after. Every quiet month waiting is one month closer to FDA for us. And we'll do a better job preparing.
It is only a matter of time before traditional laparoscopes are a thing of the past. Open or robot once the economies-of-scale get over the cost hump. Hospitals are waiting for cost-effective robotic solutions just like I am waiting for a new 4K OLED TV.
I see laparoscopes as a 3-4 decade period.
Just bought myself a new LiFePO4 performance car battery. Lithium is everywhere!
Lawyers getting involved there will roadblock any remote ability for them to get back on track. What a cluster.
The premise of Sedasys was right (using pt. feedback loops, pt. controlled hypnotic), but without the blessings of the ASA it was a road to nowhere. Only after awhile did it get limited indications, and unfortunately those were in a field where patients wanted more and more anesthesia (GI), and the indicated patient population was shrinking (ASA I/II undergoing routine (50yo+) colonoscopies...I hear we have an obesity problem in the US).
Albeit, that late, limited ASA blessing was protectionist, I am biased to say that it was rightly prudent. Something like this might work in...Japan or parts of Europe, but the idea of a BMI 38, 50yo ASA II undergoing propofol anesthesia with an anesthesia provider not in the room is a tough pill to swallow.
Yeah. The big companies want to buy proven tech. Proven in the regulatory arena and the possibly the sales arena. However, if they see a proven device that requires a high capital floor to get off the assembly line, I think they can buy before a single sale. SPORT fits this latter category.
$15 buyout ten-bags me to pay for medical school and a condo in the Philippines if this anesthetist thing goes down the pits.
Or a down payment on a beach house on the Oregon coast.
There's too much space in the robotic surgery market for the little players to compete with each other for share. That said, Surgibot is still an analog player in a digital world and it will only sell with older surgeons that don't want to leave the bedside.
The trend for surgery is going more remote. Console robotics, like UAVs to airplanes, are the future of surgery. None of my surgery resident friends care for Surgibot. They want to learn either more open or more console. Those are the routes to caring for patients further away.
R/S sends the wrong signals--it sends the signal of weakness. If the tech is legit (and it is), it shouldn't require gimmicks to raise share price just to achieve uplist prerequisites.
Mgmt. knows this stock is a short seller oasis -- as a development stock it is predictable. The only longs who will benefit from this stock are those who stick it out until the end -- a buyout or FDA approval & income. They're not going to use a R/S to fight MM. Hiring a marketing firm, attending conferences, and wisely spending raised funds to achieve milestones will do the job.
I live about 90 minutes away from John Hargrove. I will pay him a visit if they R/S.
Time to change subjects. How about the NCAA tourney?
HC is absolutely butthurt about price action on a stock. Needs a rectosigmoidectomy.
I'd be spewing the same material over and over ad nauseam on a forum board, too, but I'm not a bit concerned about SPORT and Titan Medical.
Hargrove is a wild card in this whole deal. He's either bust or boom. I won't speculate about his behind closed door policy that comes with a biotech stock that needs to tread deep competitive IP waters. Ignore what you don't know.
What we do know is what we saw at SAGES. A terrific little device. Stocks are about information. Price is based on that information. Investors have to chop through the tall grass of speculation pump & dump, short & distort swings that day traders prey upon -- and focus on the tangibles.
The other "What did I tell you?" and "Didn't I warn you?" trolls are common forum sludge after gaps down. Ignore that nonsense. They can't talk down the device.
I still think prospective buyers want to see some sort of regulatory approval -- the blessing of governments and some amount of professionals [sic]. It doesn't need to get all the way through, but good human trial outcomes at the least.
I have no doubt SPORT will do fine, but it ought to be official.
Obviously, however, the risk to a buyer is the bigger sticker price. But I'm sure Google/JNJ has a Scrooge McDuck tower of gold to draw from the necessary funds.
The people who want to invest in Titan now are those who witnessed at SAGES a surgical robot that works, will acquire regulatory approval, and will sell like hotcakes to outpatient clinics and overseas hospitals that can't afford the incumbent competition.
Development companies need cash up front. That's a matter of fact.
A lot of us here are carrying bags (I think I'm around $1.15) and see every financing deal as mgmt. being treacherous, but ultimately the math is objective and needs to add up. We still have no debt, have several completed robots, and will soon be putting those machines in human bodies. We haven't had any "bad news" since the indication adjustment, which really favors future earning potential.
Those ISRG shareholders holding $580 shares could soon very well bail those and buy TITXF for 1:1000 tomorrow morning, fill up a lot of demand. Then it is all up from there with cash on hand to complete 2016's milestones.
If this financing deal is truly considered the "last one," then theoretically that'd be the end of the abyss and it'd be all up from here, assuming CE, FDA, and sales go smooth.
If you believe this financing is that "last one," time to gobble up the shares tomorrow and for the next few days. Between us on this forum and all the SAGES visitors, who knows, people might see it as the final buying opportunity. I'm more interested in seeing what our new cash burn is with the new PR and ending device production.
I love this device and we can all speculate about mgmt., but in the end, this is a development stock. You really have to play a lot of poker at the Aria to have the guts to be long and strong on OTC biotech plays. A lower price tomorrow might be the entry point that attracts new big investors. Consider me an optimist. We're rounding the final corner.
There's downward price pressure on the entire robotic surg sector today. I wouldn't take half a day's worth of action as momentum ending. Let the conference soak the news market over the next couple days. Titan's 2016 has just begun.
Photographed weddings for 10 years using Canon DSLRs. Just bought my first Sony mirrorless...a used A7R. Purpose? Significantly reduced size and weight for travel photo work.
I say all this because that's the same future in robotic surgery. Smaller operating room footprint. Titan's SPORT embodies this movement.
I expect great things from this company, and we are so far now compared to a year ago. New indications, several built units, better marketing, and these conferences will put it all together. Can't wait for CE/FDA! Go Titan!
Well that table is going to put me (anes.) out of a job.